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Abstract
Morphine administration elicits pronounced effects on the immune system, including decreases in
natural killer (NK) cell activity and lymphocyte mitogenic responsiveness. These immune
alterations can become conditioned to environmental stimuli that predict morphine as a result of
Pavlovian conditioning processes. Prior work in our laboratory has shown that acute morphine
exposure produces dopamine-dependent reductions of NK cell activity that are mediated
peripherally by neuropeptide Y Y1 receptors. The present study examined the involvement of
dopamine D1 and neuropeptide Y Y1 receptors in the conditioned immunomodulatory effects of
morphine. Rats received two conditioning sessions during which an injection of morphine was
paired with a distinctive environment which served as the conditioned stimulus (CS). The results
show that systemic administration of the D1 antagonist SCH-23390 prior to CS re-exposure
prevented the conditioned suppression of splenic NK activity but did not alter conditioned
decreases in mitogen-induced lymphocyte proliferation. Furthermore, bilateral microinjections of
SCH-23390 directly into the nucleus accumbens shell fully blocked conditioned changes in NK
activity. In a subsequent manipulation, subcutaneous injection of the Y1 receptor antagonist
BIBP3226 prior to CS re-exposure was also shown to prevent conditioned effects on NK activity.
Collectively, these findings provide evidence that the nucleus accumbens shell plays an important
role in conditioned immunomodulation and further suggest that the conditioned and unconditioned
immunomodulatory effects of opioids involve similar receptor mechanisms.
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1. Introduction
Pavlovian (or classical) conditioning of immune responses is one of the most intriguing
examples of neural regulation of the immune system. The basic conditioning paradigm
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involves the temporal pairing of a neutral conditioned stimulus (CS), such as a novel taste,
odor, or context, with a stimulus that actively evokes an immunomodulatory response,
termed the unconditioned stimulus (UCS). Following the CS-UCS pairing, re-exposure to
the CS alone alters immune functioning in a manner which mimics the normal or
unconditioned effect of the UCS. Ader and Cohen (1975) provided one of the earliest
demonstrations of conditioned immunomodulation by showing that a gustatory stimulus
which has been paired with the immunosuppressive drug cyclophosphamide can acquire
immunosuppressive properties in mice. Subsequent investigations have demonstrated that
many immune functions are susceptible to Pavlovian conditioning, including both innate and
adaptive responses (for reviews see Ader and Cohen, 2001; Kusnecov et al., 1989).
Furthermore, conditioned immune alterations have been shown to modify disease
progression in numerous models of clinical diseases, indicating that conditioned effects on
the immune system are biologically significant (Ader and Cohen, 1982; Exton et al., 1998;
Klosterhalfen and Klosterhalfen, 1983; Lysle et al., 1992b).
Although Pavlovian conditioning of immune responses is now well established, the neural
mechanisms underlying this phenomenon are poorly understood. While there is undoubtedly
a myriad of receptors and signaling molecules involved in the mediation of complex
processes such as Pavlovian conditioning of immunity, there has been considerable interest
in the role of the endogenous opioid system. Numerous studies have shown that many of the
behavioral and physiological effects of opioid drugs can be conditioned, suggesting that the
opioid system is particularly integral to several conditioning phenomena. For instance, the
involvement of opioid receptors has been established in morphine-conditioned analgesia
(Miller et al., 1990), place preference (Piepponen et al., 1997), taste aversion (Leblanc and
Cappell, 1975), and hyperthermia (Lal et al., 1976). Notably, opioid receptors have also
been shown to mediate a number of conditioned immunomodulatory effects. Much of the
impetus for investigating the role of endogenous opioids in conditioned immunomodulation
was derived from early studies showing that the opioid antagonist naltrexone blocked
stressor-induced reductions in natural killer (NK) cell activity produced by exposure to
inescapable electric shock in rats (Cunnick et al., 1988; Shavit et al., 1984). Further studies
demonstrated that these stress-induced, opioid-mediated immune alterations could be
conditioned to the environmental context (the CS) associated with the stressful or aversive
stimulus. For example, the presentation of a CS which has previously been paired with
aversive electric shock produces naltrexone-reversible reductions in NK cell activity and
lymphocyte mitogenic responses (Lysle et al., 1992a). These conditioned immune alterations
were subsequently shown to be mediated specifically by μ-opioid receptors in the central
nervous system (CNS), providing direct evidence for the involvement of the central opioid
system in conditioned immunomodulation (Perez and Lysle, 1997).
Given the important role of the endogenous opioid system in immunomodulation, it is not
surprising that exogenously administered opioids are also capable of modulating immunity.
Morphine administration induces a host of immunomodulatory effects which are mediated
by μ-opioid receptors in the CNS (Carr et al., 1993; Fecho et al., 1996a; Shavit et al., 1986).
These pharmacological effects of morphine on immune status can also be conditioned to
environmental stimuli. For example, when rats are re-exposed to a distinctive environment
in which they have previously received morphine, immunological alterations occur that are
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similar to those produced by the drug alone, including decreased mitogen responsiveness of
blood and splenic lymphocytes, reduced interleukin-2 production, and decreased NK cell
activity in the spleen (Coussons et al., 1992). These conditioned effects are specifically
associated with re-exposure to the CS, as extensive control procedures have shown that the
immune alterations are not related to ancillary effects of the conditioning procedure. Thus,
alterations of immune status can be induced by stimuli associated with opioid
administration, indicating that any detrimental health consequences of opioid use may also
be conditioned to environmental stimuli and not solely a pharmacological property of the
drug.
There is accumulating evidence suggesting that morphine conditioned stimuli induce
immune alterations by activating the same neural pathways responsible for morphine's
unconditioned effects. For example, both conditioned and unconditioned
immunomodulatory effects of morphine are initiated by the activation of central opioid
receptors and involve increased activity of the sympathetic nervous system (Coussons-Read
et al., 1994a; Coussons-Read et al., 1994b; Fecho et al., 1996b). The sympathetic nervous
system provides a “hardwired” neuroimmune communication pathway as sympathetic fibers
directly innervate lymphoid organs and form synaptic-like contacts with splenic
lymphocytes (Felten et al., 1985; Felten and Olschowka, 1987). Thus, activation of
sympathetic nerves directly modulates immune status via the release of catecholamines and
neuropeptide Y (NPY), which interact with immunocyte cell surface receptors. Sympathetic
efferent nerves appear to be the major neuroimmune pathway responsible for immune
alterations induced by morphine and morphine conditioned stimuli. For instance,
administration of the peripherally acting β-adrenoceptor antagonist nadolol was shown to
block both the conditioned and unconditioned effects of morphine on splenocyte
proliferative responses to T and B cell mitogens (Coussons-Read et al., 1994b; Fecho et al.,
1993). However, these studies reported that neither the conditioned nor unconditioned
effects of morphine on splenic NK cell activity are attenuated by antagonism of β-
adrenoceptors.
Recent findings have demonstrated that the suppression of NK cell activity is mediated by
mechanisms distinct from those which govern morphine's effect on lymphocyte proliferative
responses. Morphine administration markedly increases extracellular dopamine levels in the
nucleus accumbens, and it appears that this effect is critically involved in the modulation of
NK cell responses. Specifically, the activation of dopamine D1 receptors in the nucleus
accumbens shell, but not core, was shown to be necessary for morphine-induced suppression
of splenic NK activity (Saurer et al., 2006a). The nucleus accumbens is intimately associated
with areas involved in autonomic regulation, suggesting that the nucleus accumbens may be
involved in the facilitation of sympathetic nervous system activity that results in morphine-
induced immune alterations. Our laboratory has recently provided evidence that peripheral
NPY Y1 receptors mediate the dopamine-dependent effects of morphine on NK activity
(Saurer et al., 2006b). This suggests that morphine-induced increases in nucleus accumbens
D1 receptor activation modulate splenic NK activity by increasing the activity of NPY-
releasing sympathetic nerves. However, whether similar mechanisms play a role in
conditioned immunomodulation is unknown. The goal of the present study was to determine
whether exposure to a CS previously associated with morphine would elicit conditioned
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immunomodulatory effects by acting via similar dopamine and NPY receptor-dependent
mechanisms. To address this issue, we evaluated the effects of the dopamine D1 antagonist
SCH-23390 and the NPY Y1 antagonist BIBP3226 on the expression of conditioned
immune alterations which were induced by environmental stimuli previously paired with the
administration of morphine.
2. Materials and methods
2.1. Animals
Adult male Lewis rats weighing approximately 200-250 grams were purchased from Charles
River Laboratories (Raleigh, NC). Upon arrival, animals were individually housed and
maintained on a reverse 12-hr light/dark cycle. Animals were habituated to handling and the
colony room environment for two weeks prior to any experimental manipulation. Food and
water were available ad libitum throughout the experiment.
2.2. Drugs
Morphine sulfate (NIDA, Bethesda, MD) and R(+)-SCH-23390 hydrochloride (Sigma-
Aldrich, St. Louis, MO) were dissolved in sterile 0.9% saline. For all experiments, morphine
was administered subcutaneously at a dose of 15 mg/kg in a 1.0 ml/kg volume. This dose
was selected based on previous studies from our laboratory showing that the effects of
morphine are dose-dependent and that the effects were blocked by naltrexone, indicating the
involvement of opioid receptors (Lysle et al., 1993). BIBP3226 (Sigma) was dissolved in
sterile water.
2.3 Conditioning Procedures
The conditioning apparatus consisted of standard rodent conditioning chambers individually
contained within sound-attenuating cubicles. The conditioning chambers provided
distinctive visual (stainless steel and plexiglass walls), tactile (wire grid floors), auditory
(white noise), and olfactory (cedar chips) cues to distinguish this environment from the
home cage.
The first experiment examined the effect of systemic administration of the dopamine D1
antagonist SCH-23390 on the expression of conditioned morphine-induced immune
alterations. All animals received two conditioning sessions separated by 48 hours, during
which an injection of morphine was paired with a distinctive environment, the conditioning
chamber. Thus, the injection of morphine served as the unconditioned stimulus (US), and
the distinctive environment served as the conditioned stimulus (CS). During each session,
rats were administered morphine immediately prior to being placed into the conditioning
chambers for 1 hour. Animals were returned to their home cages following each
conditioning session. This training phase was separated from the test day by a 12-day
recovery period during which the animals received only handling. On the test day, rats were
assigned to one of three groups (n = 8) in which they were administered saline or
SCH-23390 (0.05, or 0.5 mg/kg, s.c.). Thirty minutes following SCH-23390 administration,
half of the animals in each group were re-exposed to the CS and the other half remained in
the home cage. Thus, there were six treatment groups (n = 4) in this experiment. A previous
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study using extensive control manipulations showed that the immune alterations observed
following exposure to the conditioning chamber are the result of conditioning processes
(Coussons et al., 1992). Immediately following the test session (one hour after the onset of
CS re-exposure) animals were sacrificed by cervical dislocation and spleens were collected
for immunological assessment. Animals that remained in the home cages on the test day
were sacrificed concurrently with those that were exposed to the CS.
The second experiment examined the effect of SCH-23390 administration into the nucleus
accumbens shell prior to CS re-exposure on the conditioned immunomodulatory effects of
morphine. The conditioning procedures were identical to those described in the first
experiment. On the test day, rats received a microinjection of saline or SCH-23390 (0.15 μg/
side) into the nucleus accumbens shell. Thirty minutes following microinjection, animals
were either re-exposed to the conditioning chamber or remained in the home cage. One hour
later, animals were sacrificed to assess immune status. This experiment was replicated,
yielding an experimental design consisting of four groups (n = 10 per group).
A third experiment was performed to control for the possibility that the effect of SCH-23390
was due to diffusion of the drug into other dopamine terminal regions near the injection site.
In this experiment, the effect of bilateral SCH-23390 administration into the nucleus
accumbens core was assessed using the same procedures as described above. Animals were
assigned to one of four groups (n = 5) in which they received saline or SCH-23390 (0.15 μg/
side) into the nucleus accumbens core. Thirty minutes following microinjection, animals
were either re-exposed to the conditioning chamber or remained in the home cage. One hour
later, animals were sacrificed to assess immune status.
In the fourth experiment, the effect of subcutaneous injections of the NPY Y1 antagonist
BIBP3226 was examined. Rats received two conditioning sessions and subsequent re-
exposure to the CS exactly as described in the procedures of the first experiment, but in this
study animals received a subcutaneous injection of vehicle or BIBP3226 (0.1 or 1.0 mg/kg)
on the test day. Thirty minutes following injection, half of the animals in each dose group
were re-exposed to the CS and the other half remained in the home cages. Animals were
sacrificed one hour later. This experiment was replicated, giving an experimental design
comprised of six treatment groups (n = 4 - 6 per group).
2.4. Surgery and microinjection procedures
For the intra-accumbens microinjections, stereotaxic surgeries were performed under
anesthesia induced with a 0.2 ml intramuscular injection of a 1:1 (vol/vol) mixture of
ketamine (100 mg/ml) and xylazine (20 mg/ml). Animals were implanted with bilateral 26-
gauge guide cannulae (Plastics One, Roanoke, VA) directed toward the nucleus accumbens
shell (AP +1.7, ML ±0.8, DV –5.4) or the nucleus accumbens core (AP +1.7, ML ±1.5, DV
–4.8). Coordinates are expressed as millimeters from bregma (Paxinos and Watson, 1986).
Animals were given a one-week recovery period prior to the start of the conditioning trials.
On the testing day, animals received a bilateral injection of saline or SCH-23390 (0.15 μg/
side). SCH-23390 was administered in a 0.5 μl volume per side via a 33-gauge injector that
protruded 2 mm beyond the tip of the guide cannula (final coordinates: AP +1.7, ML ±0.8,
DV –7.4 for the shell; or AP +1.7, ML ±1.5, DV –6.8 for the core). Intracranial drug
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microinjections were performed over a 30 second period using a microsyringe pump
(Harvard Apparatus, Holliston, MA) and the injector was left in place for one minute to
allow diffusion of the drug into the injection site. Immediately following the injection,
animals were returned to the home cages.
Following sacrifice, Alcian blue dye was injected via the cannula and brains were removed
and post-fixed in 4% paraformaldehyde. Brains were then transferred to a 30% sucrose
solution for cryoprotection, frozen, and stored at −80°C for subsequent analysis. Accurate
cannulae placements were verified by examination of unstained 50 μm tissue sections under
a dissecting microscope. Only animals with placements within the targeted region were
included in the analysis.
2.5. Tissue Collection
Following sacrifice, spleens were removed and placed in 7 ml of supplemented RPMI media
(RPMI-1640 tissue culture media supplemented with 10 mM HEPES, 2 mM glutamine, and
50 μg/ml gentamicin; GIBCO, Grand Island, NY). Each spleen was prepared as a single-cell
suspension by gently pressing the tissue between two sterile, frosted microscope slides in
complete RPMI media (supplemented RPMI enriched with 10% fetal bovine serum;
GIBCO). Splenic leukocytes were counted using a Hemavet 850 cell analyzer (CDC
Technologies Inc., Oxford, CT), and cell suspensions were adjusted to 5 × 106
leukocytes/ml by diluting with complete RPMI.
2.6. Natural Killer Cell Assay
Splenic NK cell activity was assessed using a standard chromium release assay. Adjusted
splenocyte suspensions were co-incubated with the murine T-cell lymphoma, YAC-1. The
YAC-1 target cells were labeled by incubation for 70 min with 200 μCi of sodium
chromate-51 [51Cr]. YAC-1 cells were then washed three times with complete RPMI to
remove exogenous [51Cr]. Splenic leukocytes were used as effectors and were plated in
triplicate at 10, 5, 2.5, and 1.25 × 105 cells/well of a 96 well plate. Labeled targets were
diluted and plated at 1 × 104 cells/well to give effector/target (E:T) ratios of 100:1, 50:1,
25:1 and 12.5:1. Following 5 hour incubation at 37°C in a humidified CO2 incubator, the
amount of [51Cr] released into the supernatant was determined using an LKB gamma
counter (model 1272 CliniGamma). Percent specific lysis at all E:T ratios were used to
calculate lytic units (Pross and Maroun, 1984). Results are reported as the number of lytic
units per 107 effector cells. A lytic unit was defined as the number of splenic leukocytes
necessary to lyse 20% of the target cells.
2.7. Splenocyte Proliferation Assay
Mitogen stimulation assays were completed using adjusted splenocyte suspensions. Splenic
T- and B-lymphocyte proliferation was induced with the mitogens Con-A and LPS (Sigma-
Aldrich), respectively. One hundred microliters of the adjusted cell suspensions were
pipetted in triplicate into microtiter plate wells containing final concentrations of 0, 0.5, and
5.0 μg/ml Con-A and 0.5 and 5.0 μg/ml LPS. Splenocyte cultures were then incubated for 48
hours at 37°C in a humidified CO2 incubator. Each culture well was pulsed with 1 μCi of
[3H] thymidine during the last 5 hours of the incubation period. Cultures were then
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harvested onto glass fiber filter paper using a Tomtec automatic 96-well cell harvester. The
amount of [3H]-thymidine incorporated into the DNA of proliferating cells was measured
using a liquid scintillation counter (Wallac, Model 1205) and is expressed as the mean of the
triplicate disintegrations per minute (DPM) for the samples from each rat.
2.8. Statistics
Data analysis for each experiment was performed using two-way analysis of variance
(ANOVA) to assess the impact of drug antagonist treatment on conditioned immune
alterations. For the two-way analysis, the first factor was drug dosage and the second factor
was the type of treatment on the test day, i.e., re-exposure to the CS or home cage.
Experimental replication was entered into the model as a covariate to control for inter-assay
variability in the measured parameters for both the second and fourth experiments. For all
data sets, planned contrasts were performed in accordance with a priori hypotheses that
SCH-23390 and BIBP3226 would antagonize the effect of the CS. Planned contrasts in each
analysis consisted of pairwise comparisons of means between CS re-exposed groups and
home cage groups at each level of the factor “drug dosage.” All analyses were performed
with the alpha-level of significance set at p < 0.05.
3. Results
The first study examined the effect of systemic SCH-23390 administration on alterations of
immune status induced by exposure to a distinctive environment (the CS) that had been
previously paired with morphine administration. The results of the NK cell assay are shown
in figure 1. One animal was excluded from this analysis due to technical difficulties.
Analysis of variance indicated a significant main effect of CS re-exposure [F(1, 17) = 26.89;
p < 0.001]. More importantly, the analysis revealed a significant interaction between
SCH-23390 dosage and CS re-exposure [F(2, 17) = 12.54; p < 0.001], indicating that the
effect of CS re-exposure was dependent on the dose of SCH-23390. Planned contrasts
indicated that the NK activity was significantly suppressed in the CS re-exposed group
compared to the corresponding home cage control group among animals that received saline
[F(1,17) = 13.32; p < 0.01] or 0.05 mg/kg of SCH-23390 [F(1,17) = 35.64; p < 0.0001].
However, at the high dose of SCH-23390 (0.5 mg/kg), planned contrasts showed that there
was no significant difference between the groups exposed to the CS or the home cage on the
test day [F(1,17) = 0.85; p > 0.05], indicating that this dose of SCH-23390 fully blocked the
conditioned suppression of NK activity.
Figure 2 shows the results of the mitogen stimulation assays from the first experiment. Re-
exposure to the CS produced a significant decrease in splenocyte proliferation induced by
Con-A (top panel) as revealed by a significant main effect of CS re-exposure [F(1, 18) =
54.23; p < 0.0001]. Splenocyte proliferative responses to LPS (figure 2, bottom panel) were
also significantly reduced in animals re-exposed to the CS as indicated by a significant main
effect of CS re-exposure [F(1, 18) = 45.14; p < 0.0001]. There was no main effect of
SCH-23390 dosage on the proliferative responses to Con-A [F(1, 18) = 2.71; p > 0.05] or
LPS [F(1, 18) = 0.73; p > 0.05], nor was there a significant interaction between SCH-23390
dosage and CS re-exposure on responses to Con-A [F(2, 18) = 1.01; p > 0.05] or LPS [F(2,
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18) = 0.64; p > 0.05]. Furthermore, SCH-23390 administration did not antagonize the
suppressive effect of CS re-exposure on responses to Con-A or LPS at any dose tested, as
planned comparisons indicated that all groups re-exposed to the conditioning chamber on
the test day displayed significantly lower proliferation compared to the corresponding home
cage group which received the same dose of SCH-23390 or saline (ps < 0.01).
The second experiment was conducted to investigate the effect of bilateral SCH-23390
microinjections into the nucleus accumbens shell on the conditioned suppression of NK cell
activity. The results of the NK cell activity assay are displayed in figure 3A. Analysis of
variance showed a significant main effect of CS re-exposure [F(1, 32) = 18.34; p < 0.001].
More importantly, the analysis revealed a significant interaction between SCH-23390
administration and CS re-exposure [F(1, 32) = 4.92; p < 0.05], indicating that the effect of
CS re-exposure on NK activity was altered by intra-accumbens shell SCH-23390 injections.
Planned contrasts revealed that among saline treated animals, re-exposure to the CS induced
a suppression of NK activity as evidenced by a significant difference between the CS re-
exposed group and the home cage group [F(1, 32) = 20.01; p < 0.001]. However, in rats that
received SCH-23390 microinjections, planned contrasts showed that there was no difference
between the groups exposed to the CS or the home cage on the test day [F(1, 32) = 1.89; p >
0.05]. These findings show that bilateral administration of SCH-23390 at a dose of 0.15 μg/
side is sufficient to fully antagonize the conditioned suppression of splenic NK activity.
To control for the possibility of drug diffusion away from the injection site in the nucleus
accumbens shell, the effect of SCH-23390 administration into the nucleus accumbens core
was examined. The results of the NK cell activity assay from this experiment are shown in
figure 3B. Analysis of variance revealed a significant main effect of CS re-exposure [F(1,
15) = 13.31; p < 0.01], indicating that NK activity was significantly suppressed by CS re-
exposure. Planned contrasts indicated that NK activity in CS re-exposed animals was
significantly suppressed compared to the home cage group in animals which received
SCH-23390 injections into the nucleus accumbens core [F(1, 15) = 9.31; p < 0.01]. Planned
contrasts did not reveal a significant difference between the CS re-exposed group and home
cage group among animals that received saline injections [F(1, 15) = 3.70; p = 0.07].
However, there was no main effect of SCH-23390 treatment [F(1, 15) = 0.57; p > 0.05], nor
was there a significant SCH-23390 by morphine dose interaction [F(1, 15) = 0.86; p > 0.05].
Collectively, these findings suggest that D1 receptors located in the nucleus accumbens core
are not involved in the conditioned suppression of NK activity and provide additional
support for the specificity of microinjections in the shell.
Figure 4 displays the effect of subcutaneous BIBP3226 administration on the conditioned
suppression of NK activity. Analysis of variance showed a significant main effect of CS re-
exposure [F(1, 22) = 19.04; p < 0.001]. The presence of a significant interaction between CS
re-exposure and BIBP3226 dosage [F(2, 22) = 4.01; p < 0.05] indicates that the effect of CS
re-exposure on NK activity was dependent on the dosage of BIBP3226. Planned contrasts
showed that the CS re-exposed group differed from the corresponding home cage group
among animals that received vehicle [F(1, 22) = 16.89; p < 0.001] or 0.1 mg/kg of
BIBP3226 [F(1, 22) = 4.37; p < 0.05]. However, in animals that received the high dose of
BIBP3226 (1.0 mg/kg), planned contrasts showed that there was no difference between the
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home cage and CS re-exposed groups [F(1, 22) = 0.22; p > 0.05]. These findings indicate
that the 1.0 mg/kg dose of BIBP3226 fully prevents the reduction in NK activity induced by
re-exposure to the CS. It should be noted that the baseline level of NK activity was higher in
this experiment than the other experiments. Although the reason for the increase in baseline
cytolytic activity is not immediately clear, the magnitude of the conditioned effect in the
vehicle control groups was similar across all experiments.
4. Discussion
Exposure to environmental stimuli previously paired with morphine induces conditioned
immune alterations which mimic morphine's pharmacological effects. Previous studies have
established that these conditioned effects are due to the learned psychological state induced
by the CS, as development of the conditioned immunomodulatory response requires the
explicit pairing of morphine administration with the CS and is not attributable to ancillary
influences of the conditioning procedure (Coussons et al., 1992). Furthermore, it has
recently been shown that the conditioned immunomodulatory effects of heroin, an opioid
drug closely related to morphine, are susceptible to extinction and latent inhibition,
indicating that opioid-conditioned immune alterations conform to major principles of
associative learning (Szczytkowski and Lysle, 2007).
The present study shows that the conditioned suppression of NK activity is blocked by
systemic administration of the D1 antagonist SCH-23390 prior to CS re-exposure,
suggesting that morphine conditioned stimuli modulate NK activity through increased D1
receptor-mediated signaling. In contrast, SCH-23390 did not attenuate the proliferative
response of splenic lymphocytes to Con-A or LPS. This finding is notable because it shows
that the learned association between morphine and the CS is not disrupted by D1 antagonist
treatment and furthermore indicates that neuroimmune efferent communication is not
impaired in a nonspecific manner. Moreover, the selective role of D1 receptors in mediating
conditioned effects on NK activity mirrors our previous findings with morphine
administration in which SCH-23390 was shown to block the effect of morphine on NK
activity (Saurer et al., 2006a) but not lymphocyte proliferation (unpublished observations).
The current findings further demonstrate that microinjection of SCH-23390 into the nucleus
accumbens shell prior to CS re-exposure completely blocks the suppression of NK activity.
To control for the possibility that drug diffusion into neighboring brain regions was
responsible for the observed effects, SCH-23390 was also administered into the nucleus
accumbens core. This region was selected as the control injection site based on literature
documenting that the nucleus accumbens core shows a conditioned dopaminergic response
to a variety of stimuli (Cheng et al., 2003; Pezze et al., 2001). However in the present study,
microinjection of SCH-23390 into the nucleus accumbens core did not disrupt the
conditioned effect. Thus, these data indicate that the activation of D1 receptors in the
nucleus accumbens shell is necessary for the expression of the conditioned effect on splenic
NK activity. Interestingly, increased dopamine transmission in the nucleus accumbens shell
has also been widely implicated in the acquisition of associative (Pavlovian) learning (Di
Chiara et al., 2004; Pezze and Feldon, 2004). An important issue for future investigations is
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to address whether the nucleus accumbens also plays a role in the development of
associative learning processes which establish conditioned effects on immunity.
Although further studies are necessary to elucidate the precise role of the nucleus accumbens
in conditioned immune alterations, the involvement of the accumbens may simply represent
a more fundamental efferent neuroimmunoregulatory mechanism rather than being
specifically involved in conditioned effects per se. For instance, morphine's pharmacological
effect on NK activity similarly requires D1 activation in the nucleus accumbens shell (Saurer
et al., 2006a). Furthermore, prior investigations have shown that the pharmacological
stimulation of accumbens D1 receptors alone is sufficient suppress NK activity comparably
to morphine, indicating that the nucleus accumbens is intimately involved in the modulation
of peripheral immune parameters (Saurer et al., 2006b; Saurer et al., 2006a). The precise
neuroimmune efferent pathway through which accumbens D1 receptor activation elicits an
inhibition of splenic NK cell activity remains to be fully delineated, although several lines of
evidence suggest that it may involve the modulation of sympathetic nerve outflow. Neural
control of splenic NK cell activity is a well documented phenomenon which occurs
primarily via the sympathetic nervous system (Irwin et al., 1990; Katafuchi et al., 1993), and
the nucleus accumbens shell has major efferent projections to hypothalamic autonomic
regulatory centers (Heimer et al., 1991; Usuda et al., 1998). Moreover, hypothalamic nuclei
which receive direct afferent projections from the nucleus accumbens shell have been shown
to modulate NK cell activity in the spleen (Katafuchi et al., 1993; Wenner et al., 1996;
Wrona and Trojniar, 2003; Wrona and Trojniar, 2005). Thus, one possibility is that
dopamine transmission in the nucleus accumbens regulates splenic NK activity by
modulating sympathetic outflow.
Prior evidence from our laboratory has shown that NPY – a peptide transmitter released
from sympathetic fibers – mediates the dopamine-dependent modulation of splenic NK
activity. Specifically, both morphine and intra-accumbens D1 agonist administration
produce a suppression of NK activity that is prevented by blocking the activation of NPY Y1
receptors with the Y1 antagonist BIBP3226. In the present study, we show that
administration of BIBP3226 prior to CS re-exposure blocks the conditioned suppression of
NK cell activity. Because BIBP3226 reportedly does not penetrate the blood-brain barrier
when administered systemically, these findings implicate the involvement of peripheral Y1
receptors specifically (Doods et al., 1996). Given the results of our previous investigations
which indicate that Y1 receptors mediate the dopamine-dependent effects of morphine on
immune status, the current findings suggest that conditioned increases in nucleus accumbens
dopamine transmission modulates splenic NK activity by facilitating the release of NPY
from sympathetic nerves. NPY may directly interact with NK cells to inhibit cytolysis, as
splenic lymphocytes express functional Y1 receptors (Bedoui et al., 2002; Petitto et al.,
1994) and NPY produces direct and dose-dependent suppressive effects on NK activity in
vitro (Nair et al., 1993).
The involvement of NPY provides further evidence for the role of the sympathetic nervous
system in conditioned immune alterations. Although early theories suggested that
conditioned immunomodulation was simply a nonspecific stress reaction involving
activation of the hypothalamic-pituitary-adrenal axis and the release of adrenocortical
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steroids, this explanation does not adequately account for many, if not most, conditioned
effects on the immune system (e.g., Ader et al., 1979; Roudebush and Bryant, 1991). For
example, the conditioned immunosuppressive effects of cyclosporine A on T-cell
proliferation and cytokine production have been shown to be mediated solely via the
sympathetic innervation of the spleen (Exton et al., 1998). Additionally, prior studies from
our laboratory have shown that peripheral β-adrenoceptor activity mediates the conditioned
effects of both aversive stimuli and morphine on the immune system (Coussons-Read et al.,
1994b; Luecken and Lysle, 1992). Thus, the sympathetic nervous system may represent the
principal neuroimmune pathway through which a variety of conditioned stimuli induce
immune alterations, as sympathetic efferent mechanisms have been established in several
paradigms.
In conclusion, the present study demonstrates that the expression of morphine's conditioned
effects on splenic NK cell activity requires the activation of dopamine D1 receptors in the
nucleus accumbens shell. Furthermore, the current results show that antagonism of NPY Y1
receptors with BIBP3226 also prevents the conditioned suppression of NK activity. Taken
together with the results of previous investigations, the present findings provide additional
support for the hypothesis that the conditioned and unconditioned effects of morphine
involve similar mechanisms by demonstrating the involvement of similar dopamine and
NPY receptor mechanisms. Specifically, the present data suggest that conditioned increases
in the activation of nucleus accumbens D1 receptors may induce reductions in splenic NK
activity by stimulating the release of NPY. Lastly, the present study adds to our current
knowledge regarding the neural mechanisms responsible for conditioned modulation of
immunity by providing the first demonstration for the role of the nucleus accumbens in
Pavlovian conditioned immunomodulation.
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Effect of systemic dopamine D1 receptor antagonism on conditioned suppression of splenic
NK cell activity. Subcutaneous administration of SCH-23390 at a dose of 0.5 mg/kg
reversed the inhibition of splenic NK activity induced by CS re-exposure. Data are
expressed as lytic units (mean ± S.E.). Solid bars indicate rats that remained in their home
cages on the test day and open bars represent groups re-exposed to the CS on the test day. *p
< 0.01; **p < 0.001 compared with the home cage group that received the same dose of
SCH-23390.
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Effect of systemic D1 receptor antagonism on conditioned suppression of lymphocyte
proliferation. Subcutaneous SCH-23390 administration did not attenuate the inhibitory
effect of CS re-exposure on splenocyte mitogenic responses to Con-A (5.0 μg/ml) or LPS
(5.0 μg/ml). Data are expressed as disintegrations per minute (mean ± S.E.). Solid bars
indicate rats that remained in their home cages on the test day and open bars represent
groups re-exposed to the CS on the test day. *p < 0.01; **p < 0.001 compared with the
home cage group that received the same dose of SCH-23390.
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Effect of D1 receptor antagonism in the nucleus accumbens shell (A) or core (B) on
conditioned suppression of NK cell activity. A, Bilateral injections of SCH-23390 into the
nucleus accumbens shell blocked the inhibitory effect of CS re-exposure on NK activity. B,
Administration of SCH-23390 into the nucleus accumbens core did not prevent the effect of
CS re-exposure. Solid bars indicate rats that remained in their home cages on the test day
and open bars represent groups re-exposed to the CS on the test day. Data are expressed as
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lytic units (mean ± S.E.). *p < 0.01; **p < 0.001 compared with the home cage group that
received the same dose of SCH-23390.
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Effect of NPY Y1 receptor antagonism on conditioned reductions of NK cell activity.
Subcutaneous administration of BIBP3226 at a dose of 1.0 mg/kg blocked the inhibition of
splenic NK activity induced by CS re-exposure. Solid bars indicate rats that remained in
their home cages on the test day and open bars represent groups re-exposed to the CS on the
test day. *p < 0.05; **p < 0.001 compared with the home cage group that received the same
dose of BIBP3226.
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